Abstract:ObjectiveTo evaluate the magnetic resonance (MR) image artifact and image distortion associated with the two transcutaneous bone conduction implants currently available in the United States.Study DesignCadaveric study.MethodsTwo cadaveric head specimens (1 male, 1 female) were unilaterally implanted according to manufacturer guidelines and underwent MR imaging (General Electric and Siemens 1.5 T scanners) under the following device conditions: (1) no device, (2) Cochlear Osia with magnet and headwrap, (3) Coch… Show more
“…If considering placement of transcutaneous boneconduction implants, it is important to consider implications on postoperative imaging surveillance of carcinoma or development of cholesteatoma. Recent work demonstrated substantial imaging artifact associated with transcutaneous bone-conduction implants when attempting diffusion-weighted imaging for cholesteatoma surveillance, and protocol modifications are required for adequate imaging using T1/ T2-weighted sequences [30]. Furthermore, placement of a transcutaneous bone-conduction implant introduces the potential for radiation scatter or attenuation [31], although this has not been studied specifically for the newer transcutaneous bone-conduction implants to date.…”
Purpose of review
The purpose of this review is to outline the temporal bone management of external and middle ear carcinoma. The review will outline the current evidence involved in deciding which surgical approach to take, as well as new advances in auditory rehabilitation and immunotherapy.
Recent findings
Traditional surgical approaches include lateral temporal bone resection, subtotal temporal bone resection and total temporal bone resection. They can also involve parotidectomy and neck dissection depending on extension of disease into these areas. Options for auditory rehabilitation include osseointegrated hearing aids, transcutaneous bone-conduction implants, and active middle ear implants. Recent advances in immunotherapy have included the use of anti-PD-1 monoclonal antibodies.
Summary
The mainstay of management of temporal bone disease involves surgical resection. Early-stage tumours classified according to the Pittsburgh staging tool can often be treated with lateral temporal bone resection, whereas late-stage tumours might need subtotal or total temporal bone resection. Parotidectomy and neck dissection might also be indicated if there is a risk of occult regional disease. Recent advances in immunotherapy have been promising, particularly around anti-PD-1 inhibitors. However, larger clinical trials will be required to test the extent of efficacy, particularly around combination use with surgery.
“…If considering placement of transcutaneous boneconduction implants, it is important to consider implications on postoperative imaging surveillance of carcinoma or development of cholesteatoma. Recent work demonstrated substantial imaging artifact associated with transcutaneous bone-conduction implants when attempting diffusion-weighted imaging for cholesteatoma surveillance, and protocol modifications are required for adequate imaging using T1/ T2-weighted sequences [30]. Furthermore, placement of a transcutaneous bone-conduction implant introduces the potential for radiation scatter or attenuation [31], although this has not been studied specifically for the newer transcutaneous bone-conduction implants to date.…”
Purpose of review
The purpose of this review is to outline the temporal bone management of external and middle ear carcinoma. The review will outline the current evidence involved in deciding which surgical approach to take, as well as new advances in auditory rehabilitation and immunotherapy.
Recent findings
Traditional surgical approaches include lateral temporal bone resection, subtotal temporal bone resection and total temporal bone resection. They can also involve parotidectomy and neck dissection depending on extension of disease into these areas. Options for auditory rehabilitation include osseointegrated hearing aids, transcutaneous bone-conduction implants, and active middle ear implants. Recent advances in immunotherapy have included the use of anti-PD-1 monoclonal antibodies.
Summary
The mainstay of management of temporal bone disease involves surgical resection. Early-stage tumours classified according to the Pittsburgh staging tool can often be treated with lateral temporal bone resection, whereas late-stage tumours might need subtotal or total temporal bone resection. Parotidectomy and neck dissection might also be indicated if there is a risk of occult regional disease. Recent advances in immunotherapy have been promising, particularly around anti-PD-1 inhibitors. However, larger clinical trials will be required to test the extent of efficacy, particularly around combination use with surgery.
“…3 Had there been any concerns about need for future MRI of the head (e.g., cholesteatoma in a patient with stenosis rather than atresia or an underlying syndrome) we would recommend doing this first as the metal artefact from the device makes future MRI assessment of the middle ear impossible without prior removal. 4 We ask all our patients to review a dummy device and processor held against the head in the mirror to ensure they are happy with the appearance. In our experience, the device is larger than they expect, particularly for children.…”
The Cochlear™ Osia ® 2 System (Osia; Cochlear, Sydney, Australia) is a new generation of an active transcutaneous bone-anchored hearing implant which utilises a piezoelectric transducer that is fixed to a titanium implant (BI300). The utilisation of piezoelectric stimulation allows for bone conduction hearing loss of up to 55 dB. The device
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.